Mayne Pharma Signs 20-Year Exclusive License and Supply Agreement for Novel Oral Contraceptive in the US

Wednesday, October 2, 2019 General News
Email Print This Page Comment bookmark
Font : A-A+

[1] CHCs contain estrogen plus progestin and are short-acting oral contraceptives, vaginal rings or patches.

[2] IQVIA, MAT Sales and NSP Units July 2019. A single unit is equivalent to one 28-day cycle.

[3] Annual net sales of NUVARING and LO LOESTRIN FE in the US in 2018 were US$722 million and US$528 million respectively.

[4] Actual number of shares issued at closing and regulatory approval is 168.9 million and is based on 9.6% of the expanded capital base. The equity value at closing is US$28.7 million based on 83.1 million issued shares, AUD:USD rate of 0.675 and a 10-day VWAP share price of A$0.511.

[5] Subject to certain limited exceptions



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Search

Premium Membership Benefits

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store